# Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

> **NCT03821038** · PHASE2 · TERMINATED · sponsor: **Revimmune** · enrollment: 21 (actual)

## Conditions studied

- Sepsis, Severe

## Interventions

- **BIOLOGICAL:** CYT107
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03821038
- **Lead sponsor:** Revimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-01
- **Primary completion:** 2021-10-06
- **Final completion:** 2021-10-06
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** PK issue detected after bolus IV route administration
- **Last updated:** 2021-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03821038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03821038, "Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03821038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*